METASTATIC PANCREATIC CANCER

This study tests a tiny radiation device placed directly into pancreatic tumors, combined with standard chemotherapy. It aims to see if the treatment is safe and helps control pain. About 40 people with advanced or spread pancreatic cancer will take part.

This study tests a new approach for advanced pancreatic cancer that cannot be removed by surgery. Doctors place tiny devices called Alpha DaRT seeds directly into the tumor to deliver a special type of radiation from the inside. The main goals are to see if the procedure is safe …

This study tests whether adding two extra drugs (surufatinib and camrelizumab) to standard chemotherapy can help people with metastatic pancreatic cancer live longer and control their disease better. About 500 adults aged 18-75 who have not had prior treatment for their advanced …

This early-phase study tests a new drug called IPH5301 in people with advanced solid tumors that have spread. The drug works by blocking a protein (CD73) that tumors use to hide from the immune system. The study first finds the safest dose of IPH5301 alone, then tests it combined…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. The study includes adults with certain cancers and children aged 12…

This early-stage study tests the safety of a new drug called ERX-315 in 15 adults with advanced solid tumors (such as breast, ovarian, or pancreatic cancer) that have stopped responding to approved therapies. The main goal is to find safe doses and watch for side effects, not to …

This study is for people with untreated metastatic pancreatic cancer that has spread to other parts of the body. Participants first receive a low-dose combination of five chemotherapy drugs, then continue with two maintenance medications (olaparib and pembrolizumab) to help keep …

This study tests a mix of four drugs (iparomlimab, tuvonralimab, chidamide, and chemotherapy) as a first treatment for people with metastatic pancreatic cancer that has spread. The goal is to see if the combination can shrink tumors and help people live longer. The trial is for 3…

This early-stage trial tests whether adding Tumor Treatment Fields (TTF) – a device that sends low-intensity electric fields to the tumor – to a three-drug chemotherapy regimen can help control metastatic pancreatic cancer. About 40 adults whose cancer has spread to the liver wil…

This study tests whether giving two different chemotherapy regimens one after the other (first Gembrax, then Folfirinox) helps people with metastatic pancreatic cancer live longer without their disease getting worse, compared to using Folfirinox alone. About 162 adults aged 18 to…

This study tests a drug called Kinisoquin to see if it can prevent dangerous blood clots in people with advanced pancreatic cancer. About 480 adults with metastatic or locally advanced pancreatic cancer who are starting chemotherapy will receive either Kinisoquin or a placebo. Th…

This study tests a new treatment for people with advanced cancers of the digestive tract, breast, ovary, or other organs. Doctors take immune cells from a patient's tumor, grow them in a lab, and give them back along with a drug called pembrolizumab. The goal is to see if this co…

This early-phase study tests a new treatment for people with metastatic pancreatic or breast cancer that has stopped responding to standard therapies. The treatment combines two chemotherapy drugs with high-dose vitamins and a stem cell transplant to help the body recover. The ma…

This early-phase study tests a two-part approach for people with advanced pancreatic cancer. First, a special imaging scan helps find tumors; then, a targeted radioactive treatment is given to try to control the disease. The study enrolls 30 adults whose cancer has spread or cann…

This study tests whether adding the experimental drug setidegrasib to standard chemotherapy helps people with a specific genetic form of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 614 adults whose cancer has spread and cannot be removed by surgery will rec…

This study tests if adding a low-dose EGFR blocker (erlotinib) to standard chemotherapy works better for people with a specific type of advanced pancreatic cancer called 'basal-like.' Participants first get a test to classify their tumor. Those with basal-like cancer may receive …

This study aims to find genetic changes in the tumors of 750 people with advanced or metastatic pancreatic cancer. By identifying these changes, doctors hope to match patients with targeted treatments that may work better for them. The study does not test a new drug but collects …